


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claim 1. (canceled)

Claim 2. (currently amended) A compound of the formula



wherein  $R_1$  is independently selected from the group consisting of H; alkyl; substituted alkyl; alkoxy; halo; substituted alkoxy; hydroxy; trifluoralkyl; nitro; amino; alkylamino; cycloalkylamino; cyano; carboxy; cycloalkyl; phenyl; and substituted phenyl;


$R_2$  is independently selected from the group consisting of H; alkyl; substituted alkyl; halo; heterocycloalkyl; heteroaryl; phenyl; substituted phenyl; naphthyl and substituted naphthyl;

$B_1$  is hydrogen;


$B_2$  is hydrogen; or  $B_1$  and  $B_2$  are methylene and joined together to form a five or six membered ring;

$Y$  is methylene or carbonyl;


- L is selected from the group consisting of  
C<sub>1-8</sub>alkylene; C<sub>2-10</sub>alkenylene; C<sub>2-10</sub>alkynylene; C<sub>3-7</sub>cycloalkylene;  
C<sub>3-7</sub>cycloalkylC<sub>1-4</sub>alkylene;  
arylC<sub>1-4</sub>alkylene;  
 $\alpha$ -aminoC<sub>4-7</sub>alkylene;




- (N-methylene)piperidin-4-yl;




- (N-methylene)piperazin-4-yl;




- (N-methylene)pyrrolidin-3-yl;



- (N-methylene)-4-acetyl-piperidin-4-yl;




and (N-methylene)piperidin-4,4-diyl;




Z is selected from the group consisting of


aryl;




N-sulfonamido;




N-(aryl)sulfonamido;




arylamido;




arylureido;




arylacetamido:




(aryloxy)carbonylamino;



2,3-dihydro-2-oxo-1*H*-benzimidazol-1-yl;



and 1-aryl-2,3-dihydro-4-oxo-imidazol-5,5-diyl;



$R_3$  is independently selected from the group consisting of  $C_{1-6}$  alkyl; substituted  $C_{1-6}$  alkyl; cycloalkyl; substituted cycloalkyl; naphthyl; substituted naphthyl; heteroaryl; and substituted heteroaryl;

$R_4$  is independently selected from the group consisting of hydrogen;

C<sub>1-8</sub>alkyl; C<sub>1-8</sub>alkoxy; substituted C<sub>1-8</sub>alkoxy; hydroxy; halogen; cyano; nitro; amino; C<sub>1-8</sub>alkylamino; and C<sub>1-8</sub>dialkylamino;

R<sub>5</sub> is independently selected from the group consisting of hydrogen; C<sub>1-8</sub>alkyl; C<sub>1-8</sub>alkylcarbonyl; aroyl; carbamoyl; amidino; C<sub>1-8</sub>alkyl; C<sub>1-8</sub>alkylaminocarbonyl; (aryl amino)carbonyl; and arylC<sub>1-8</sub> alkylcarbonyl;

R<sub>6</sub> is independently selected from hydrogen and C<sub>1-8</sub>alkyl;

n is 1-2;

m is 0-3;


p is 1-3; and

q is 1-3;


provided that when Z is aryl or heteroaryl, L is (N-methylene)piperazin-4-yl or (N-methylene)-4-acetylpiperidin-4-yl; provided that when L is (N-methylene)piperazin-4-yl, Z is phenyl or naphthyl; when L is (N-methylene)-4-acetylpiperidin-4-yl, Z is phenyl or naphthyl and Y is carbonyl; and when Z is N-sulfonamido or N-(aryl)sulfonamido, L is α-aminoC<sub>4-7</sub>alkylene, (N-methylene)piperidin-4-yl or (N-methylene)pyrrolidin-3-yl;

and enantiomers, diastereomers and pharmaceutically acceptable salts thereof.

Claim 3. (previously presented) A compound of claim 2 selected from the group consisting of:




Claim 4. (previously presented) A compound of claim 2 selected from the group consisting of:



and

Claim 5. (previously presented) A compound of claim 2 selected from the group consisting of:



and




Docket No. ORT-1588  
Serial No. 10/071,483

Claim 6. (canceled)






Claim 7. ( canceled)

Claim 8. (previously presented) A compound of claim 2 selected from the group consisting of:



and

Claim 9. (previously presented) A compound of claim 2 selected from the group consisting of:




and

Docket No. ORT-1588  
Serial No. 10/071,483

Claim 10. (canceled)

Claim 11. (canceled)

Claim 12. (previously presented) A compound of claim 2 selected from the group consisting of:



and

Claim 13. (canceled)

Claim 14. (canceled)

Claim 15. (canceled)

Claim 16. (canceled)

Claim 17. (previously presented) A method of treating disorders and diseases associated with NPY receptor subtype 5 comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of claim 2.

Claim 18. (previously presented) A pharmaceutical composition for the treatment of diseases or disorders associated with the NPY Y5 receptor subtype comprising a therapeutically effective amount of a compound of claim 2 and a pharmaceutically acceptable carrier.

Claim 19. (currently amended) A pharmaceutical composition according to claim 18 for the treatment of disorders or disease states caused by eating disorders, obesity, ~~bulimia nervosa~~, diabetes, memory loss, epileptic seizures, migraine, sleep disturbances, pain, sexual/reproductive disorders, depression and anxiety.